within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02A_HormonesAndRelatedAgents.L02AE05_Histrelin;

model Histrelin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.055555555555555e-06,
    adminDuration = 600,
    adminMass = 1 / 1000000,
    adminCount = 1,
    Vd = 0.0441,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0363,
    k12 = 4.194444444444445e-06,
    k21 = 4.194444444444445e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Histrelin</td></tr><tr><td>ATC code:</td><td>L02AE05</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>44.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Histrelin is a potent gonadotropin-releasing hormone (GnRH) agonist used primarily in the treatment of hormone-sensitive conditions such as central precocious puberty in children and advanced prostate cancer in adults. It is typically delivered as a subcutaneous implant for sustained drug release and is approved for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived in adult healthy male subjects after a single intravenous infusion of histrelin.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L02AE05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Histrelin;
